Associate Professor Chris Ormandy
Principal Research Fellow; Group Leader, Cancer Research Program, Garvan Institute of Medical Research; Conjoint Senior Lecturer, Department of Medicine, The University of New South Wales
Email: c.ormandy 'at' garvan.org.au
Research Group: Mammary Development
Education
1992 PhD ,The University of New South Wales
1984 BSc (Hons), University of Sydney
Selected Publications
Ormandy CJ, Camus A, Barra J, Damotte D, Lucas B, Buteau H, Edery M, Brousse N, Babinet C, Binart N and Kelly PA (1997). Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev 11: 167-78.
Brisken C, Kaur S, Chavarria TE, Binart N, Sutherland RL, Weinberg RA, Kelly PA and Ormandy CJ (1999). Prolactin controls mammary gland development via direct and indirect mechanisms. Dev Biol 210: 96-106.
Lindeman GJ, Wittlin S, Lada H, Naylor MJ, Santamaria M, Zhang JG, Starr R, Hilton DJ, Alexander WS, Ormandy CJ and Visvader J (2001). SOCS1 deficiency results in accelerated mammary gland development and rescues lactation in prolactin receptor-deficient mice. Genes Dev15: 1631-6.
Sainsbury A, Schwarzer C, Couzens M, Jenkins A, Oakes SR, Ormandy CJ and Herzog H (2002). Y4 receptor knockout rescues fertility in ob/ob mice. Genes Dev16: 1077-88.
Zhou J, Chehab R, Tkalcevic J, Naylor MJ, Harris J, Wilson TJ, Tsao S, Tellis I, Zavarsek S, Xu D, Lapinskas EJ, Visvader J, Lindeman GJ, Thomas R, Ormandy CJ, Hertzog PJ, Kola I and Pritchard MA (2005). Elf5 is essential for early embryogenesis and mammary gland development during pregnancy and lactation. Embo J24: 635-44.
Harris J Stanford PM, Sutherland K, Oakes SR, Naylor MJ, Robertson FG, Blazek KD, Kazlauskas M, Hilton HN, Wittlin S, Alexander WS, Lindeman GJ, Visvader JE and Ormandy CJ. (2006) Socs2 and Elf5 mediate prolactin-induced mammary gland development. Mol Endocrinology 201177-1187.
Oakes SR, Robertson FG, Kench JG, Gardiner-Garden M, Wand MP, Green JE and Ormandy, CJ. (2007) Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions. Oncogene26: 543-553.
Oakes SR, Naylor, MJ, Asselin-Labat Blazek KD, Gardiner-Garden M, Hilton H, Kazlauskas K, Pritchard M, Chodosh L, Pfeffer P, Lindeman G, Visvader J and Ormandy CJ.(2008) The ets transcription factor Elf5 specifies mammary alveolar cell fate. Genes and Development 22:581-586
Alles CM, Gardiner-Garden M, Nott DJ et al. (2009) Meta-analysis and gene set enrichment relative to ER status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup. PLoS One; 4(3):e4710.
Schramek D, Leibbrandy A, Sigl V et al. (2010) The osteoclast differentiation factors RANKL/RANK control development of progesterone-driven breast cancer. Nature; 468:98-102.
Lee HJ, Hinshelwood RA, Bouras T et al. (2011) Lineage specific methylation of the Elf5 promoter in mammary epithelial cells. Stem Cells: doi:10.1002/stem.706.
